Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Poisoning one’s political rivals has a long history. In 399 B.C., an Athenian court found Socrates guilty of “impiety and the corruption of youth” and ordered him to drink a fatal dose of hemlock.

Long-term analysis suggests follicular lymphoma can be cured, Fred Hutch study finds

Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma, has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell patients to expect it to come back. The results from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma could upend that prediction.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Oral mezigdomide in combination with carfilzomib and dexamethasone demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to positive interim phase III results from the SUCCESSOR-2 study.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Medically supervised, individualized nutrition therapy—long proven effective in reversing metabolic diseases like type 2 diabetes and obesity—shows promise in extending survival in patients with metastatic pancreatic cancer when used alongside chemotherapy, according to data from a randomized, controlled phase II clinical trial.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.

March 13, 2026

Vol.52 No.10

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

YOU MAY BE INTERESTED IN

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Long-term analysis suggests follicular lymphoma can be cured, Fred Hutch study finds

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Renew today!

Subscriber content

Never miss an issue!

Login

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

YOU MAY BE INTERESTED IN

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisonsA gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Long-term analysis suggests follicular lymphoma can be cured, Fred Hutch study finds

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM

Nutrition therapy extends survival by 34% in stage 4 pancreatic cancer patients, clinical trial shows

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Never miss an issue!

Login

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison